Related Experiment Video
Updated: May 23, 2026
08:55
Characterization of Multi-subunit Protein Complexes of Human MxA Using Non-denaturing Polyacrylamide Gel-electrophoresis
Published on: October 28, 2016
Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex
1Therex, TIMC-IMAG, CNRS Université Joseph Fourier, UMR 5525, Grenoble, France.
Haematologica
|April 12, 2012
Summary
Gla-domainless factor Xa effectively restored thrombin generation in hemophilia A and B patient plasma, suggesting it as a potential new treatment for hemophilia. This modified factor Xa offers a promising alternative for patients with or without inhibitors.
Area of Science:
- Biochemistry
- Hematology
- Pharmacology
Background:
- Hemophilia arises from deficiencies in coagulation factors VIII or IX, impairing intrinsic and extrinsic tenase complexes.
- Factor Xa (FXa) inhibition by tissue factor pathway inhibitor (TFPI) further complicates coagulation in hemophilia.
- Gla-domainless FXa, a modified FXa lacking procoagulant activity, was investigated for its interaction with TFPI and its effect on extrinsic tenase inhibition.
Purpose of the Study:
- To assess the capacity of Gla-domainless FXa to restore thrombin generation in hemophilia plasma.
- To compare the efficacy of Gla-domainless FXa with TFPI and antithrombin depletion.
- To analyze the neutralization kinetics of FXa and Gla-domainless FXa by antithrombin and TFPI.
Main Methods:
- Thrombin generation assay using low tissue factor concentration in hemophilia A and B plasma (with/without inhibitors).
- Comparative analysis of Gla-domainless FXa efficacy against antithrombin and TFPI depletion.
- Kinetic studies on the neutralization of FXa and Gla-domainless FXa by antithrombin and TFPI.
Main Results:
- Gla-domainless FXa successfully restored thrombin generation in all tested hemophilia plasma samples.
- It demonstrated lower affinity for TFPI compared to native FXa, while antithrombin affinities were similar.
- Despite a short plasma half-life, Gla-domainless FXa sustained thrombin generation for over an hour.
Conclusions:
- Gla-domainless FXa shows potential as an effective therapeutic agent for hemophilia.
- Its ability to restore thrombin generation offers a promising alternative for hemophilia patients, including those with inhibitors.
- Further research may validate Gla-domainless FXa as a novel treatment strategy for coagulation factor deficiencies.
